USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: Nova Pharmaceutical Corp
City: Baltimore
State: MD
Zip+4: 21224
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $507,550.00 11
SBIR Phase II $801,804.00 2

Award List:

EXCITATORY AMINO ACID ANTAGONISTS AS ANTIEPILEPTIC DRUGS

Award Year / Program / Phase: 1984 / SBIR / Phase I
Agency: HHS
Principal Investigator: David C. U'prichard
Award Amount: $37,200.00

EXCITATORY AMINO ACID ANTAGONISTS AS ANTIEPILEPTIC DRUGS

Award Year / Program / Phase: 1985 / SBIR / Phase II
Agency: HHS
Principal Investigator: David C. U'prichard
Award Amount: $354,455.00
Abstract:
This is a phase i proposal where funding is sought to assist in the setting up of a drug discovery and development program by nova pharmaceutical corporation leading to new and improved drugs to treat epilepsy. although there are currently 16 major types of antiepileptic medications in use in the… More

THE PREVALENCE OF OBESITY IN THE U.

Award Year / Program / Phase: 1986 / SBIR / Phase I
Agency: HHS
Principal Investigator: Diane l dehaven , PRINCIPAL INVESTIGATOR
Award Amount: $33,000.00
Abstract:
The prevalence of obesity in the u.s. population (26% of people in all age groups) and its increased risk for life- threatening or chronic diseases, such as cancer, hyper- tension, and heart disease, have caused the nih in 1985 to declare obesity a disease. unfortunately, predictable pharmacologic… More

NOVEL APPETITE SUPPRESSANTS: DISCOVERY AND DEVELOPMENT

Award Year / Program / Phase: 1988 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $50,000.00
Abstract:
The search for a pharmacological agent that will facilitate weight reduction remains as one of the most challenging areas of drug development. animal and human data provide sound evidence that body weight is regulated around a physiological "set point," and to date those therapeutic approaches that… More

GABA(B) RECEPTOR AGONISTS AND ANTAGONISTS

Award Year / Program / Phase: 1988 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $50,000.00
Abstract:
Evidence suggests receptors mediating cns responses to -aminobutyric acid (gaba) are heterogeneous and the designations of gaba(a) and gaba(b) have been advanced to differentiate major receptor subtypes. gaba(a) receptorsare antagonized by bicuculline (bic), linked to a picrotoxin(pic)-sensitive… More

NONCOMPETITIVE NMDA RECEPTOR ANTAGONISTS

Award Year / Program / Phase: 1988 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $46,000.00
Abstract:
Substantial evidence indicates that excitatory amino acid (eaa) neurotransmission plays a role in the pathophysiology of epilepsy, neurodegenerative disorders and the neuronal damage that occurs following hypoxic or ischemic cns insult.of the three recognized eaa receptor subtypes (quisqualate,… More

DEVELOPMENT OF CORTICOTROPIN-RELEASING FACTOR ANTAGONISTS

Award Year / Program / Phase: 1988 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $46,000.00

INTERLEUKIN 1 REGULATION OF BRADYKININ RECEPTORS

Award Year / Program / Phase: 1989 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $49,611.00
Abstract:
Bradykinin (bk), synthesized following many pathological insults, causes smooth muscle contraction, increased vascular permeability, and stimulation of neuronal pain receptors, actions generally mediated through b2 receptors. in some animal disease models, there appears in vascular smooth muscle a… More

DEVELOPMENT OF CORTICOTROPIN-RELEASING FACTOR ANTAGONISTS

Award Year / Program / Phase: 1990 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $447,349.00
Abstract:
Corticotropin-releasing factor (crf), a 41-amino acid peptide, acting at specific receptors in the brain and pituitary has been demonstrated to initiate behavioral, physiological and neuroendocrine responses that mimic the response to stress in animals. in addition to its physiological role in… More

NOVEL CEREBROPROTECTIVE AGENTS

Award Year / Program / Phase: 1990 / SBIR / Phase I
Agency: HHS
Principal Investigator: Michael J Pontecorvo
Award Amount: $49,159.00
Abstract:
There currently exists no effective prophylactic or post-hoc pharmacotherapy for minimizing ischemia-induced neuronal damage. more than one million people in america are believed to suffer neuronal damage and physical and cognitive impairments as a consequence of ischemia associated with chronic… More

CHARACTERIZATION OF KAINATE & AMPA RECEPTOR ANTAGONIST

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Edward Karbon Jr
Award Amount: $49,669.00
Abstract:
Stroke is the most prominent cns disorder in the united states as well as the leading cause of disability and the third leading cause of death. however, there are no effective treatments available to prevent or reduce neuronal damage resulting from stroke or other forms of cerebral ischemia.… More

IDENTIFICATION OF SIGMA ANTAGONISTS

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Edward Carbon Jr
Award Amount: $49,911.00
Abstract:
Dopamine (d2) receptor antagonists such as haloperidol and chlorpromazine are most commonly used to treat schizophrenia. however, both acute and chronic administration of these drugs can result in the appearance of extrapyramidal side effects (eps) which, like the therapeutic effects of these drugs,… More

DEVELOPMENT OF ENDOTHELIN-1 ANTAGONISTS

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Sweetnam, Paul M , Principal Investigator
Award Amount: $47,000.00
Abstract:
Endothelin-1 (et-1), a 21 amino acid peptide, acting at specific receptors in vascular tissues has been demonstrated to initiate such physiological responses as: decreases/increases in systemic arterial pressure, alterations in local blood distribution, renal function (i. e. formation and… More